Clinical Trials
40 trialsReLUTH
Institut du Cancer de Montpellier - Val d'Aurelle
LUPARPED
Fundación de investigación HM
Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors
National Cancer Institute (NCI)
Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
National Institutes of Health Clinical Center (CC)
Using Novel Imaging to More Safely Treat Neuroendocrine Tumors
University of Wisconsin, Madison
Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors
National Cancer Institute (NCI)
Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors
National Cancer Institute (NCI)
Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver
Memorial Sloan Kettering Cancer Center
REAL-LU
Novartis
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
National Institutes of Health Clinical Center (CC)
Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors
Providence Health & Services
GoTHAM
Melanoma and Skin Cancer Trials Limited
NELMAS
Imperial College London
SALUS
Advanced Accelerator Applications
Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors
University Health Network, Toronto
LANTana
Imperial College London
A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs
Sinotau Pharmaceutical Group
Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases
University of California, San Francisco
RIALTO
Grupo Espanol de Tumores Neuroendocrinos
LUMOD-ID
University of Iowa
Comparing 177Lu-Dotatate/Capecitabine Combination Treatment With 177Lu-Dotatate in Neuroendocrine Tumor Patients
Erasmus Medical Center
LUNET
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
DOBATOC
University of Aarhus
P-PRRT
CHU de Quebec-Universite Laval
SPORE-3
University of Iowa
NeoLuPaNET
IRCCS San Raffaele
Phase II Study to Evaluate the Efficacy and Safety of 177Lu-Dotatate in the First-line Treatment of Patients With Locally Advanced or Metastatic, Somatostatin Receptor-positive G2 or G3 Gastroenteropancreatic Neuroendocrine Tumors
Peking University
Retrospective Analysis of Patients Re-treated With Lutetium-177 DOTATATE (Lutathera®)
Novartis
Radio-Marker
Erasmus Medical Center
177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms
Excel Diagnostics and Nuclear Oncology Center
SEPTRALU
Sociedad Española de Medicina Nuclear e Imagen Molecular
LUMEN
Jules Bordet Institute
LUTIA
UMC Utrecht
A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours
Fundación de investigación HM
NETTER-1
Advanced Accelerator Applications
Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents
University of Iowa
POLNETS_PRRT
University of Warmia and Mazury
EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx
Advanced Accelerator Applications
CASTOR
Jules Bordet Institute
NEO-LEBE
University of Jena